ArticleJournal of gastrointestinal oncology2023

Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201.

Shin Takahashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.